Skip to main content

Advertisement

Figure 3 | Retrovirology

Figure 3

From: In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

Figure 3

Effect of the number of shRNA, efficacy, marking and level of inhibition on cellular compartments. Cells within each compartment are expressed as a percentage of all cells and monitored over 5000 days. Scenarios include: A) 6 shRNAs (S1), B) 4 shRNAs (S2), C) 2 shRNAs (S3), D) 60n % efficacy (S4), E) 1% marking (S5) and F) Class II inhibition only (S11). Assumptions for each scenario are indicated where - x = number of shRNA, - e = efficacy, - HSC+ = hematopoietic stem cells transduced to contain the gene therapeutic and - f = fitness.

Back to article page